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Critique of:
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Background
There are about 16,000–17,000 renal transplants per year in the 
United States. Greater than 60% are deceased donor transplants. 
Up to 50% of these cases are complicated by delayed graft function 
(DGF), characterized by a requirement for dialysis in the recipi-
ent within 7 days after renal transplant. DGF is associated with an 
increased risk for an acute rejection episode. It is an independent 
risk factor for decreased graft survival and prolonged. Ischemia–
reperfusion injury during the transplantation process is also a major 
contributing factor to subsequent poor allograft function. 
Methods
Intervention was initiated after research authorization was 
obtained. The investigators randomized donors declared deceased 
by neurologic criteria (DNC) to normothermia (36.5–37.5C) versus 
hypothermia (34–35C). The goal was to reach the target tempera-
ture within 4 hours of enrollment and maintain temperature until 
transport to the operating room. The primary outcome measure was 
DGF. The secondary outcome measures were the rate of individual 
organs transplanted in each treatment group and the number of 
organs transplanted from each enrolled donor.
Objective
To investigate the potential benefit and safety of normothermia vs. 
targeted hypothermia (36.5–37.5 versus 34–35 degrees C) in donors 
with respect to rates of delayed graft function among transplant 
recipients.
Design
Prospective, randomized, controlled trial.
Setting
Patients who met DNC from two large organ-donation service areas 
March 20, 2012 and October 17, 2013.
Subjects
394 donors who met DNC criteria were identified by two organ-
procurement organizations: Northern California and Nevada- 
California Transplant Donor Network and Southern California and 
Nevada One Legacy. Legal statutes do not require informed consent.
Analysis
The initial plan was to enroll 500 donors. This would provide a 
90% power to detect a 30% relative difference in the rate of 
delayed graft function between the study groups. The investigators 
had a scheduled pre-planned interim analysis for efficacy or futil-
ity in the 5th quarter of the study period. The primary outcome sub 
group comparison utilized the t test and Fisher’s exact. For the 
secondary outcomes chi-square test was utilized. The preplanned 
interim analysis used a logistic-regression model for delayed graft 
function with adjustment for covariates including donor creatinine 
level at enrollment, organ-procurement agency, donor age, cold-
ischemia time and donor type (Standard Criteria Donors versus 
Extended Criteria Donors). The primary efficacy analysis included 
all transplanted kidneys with known cold-ischemia time and 
outcome data on delayed graft function in the recipients.
Results
The interim analysis showed benefit of hypothermia, prompting 
early termination of the study. 370 total organ donors were enrolled. 
180 were randomized to hypothermia, and 190 to normothermia. 
572 patients received a kidney transplant. This included 285 kidneys 
from donors in the hypothermia group and 287 kidneys from donors 
in the normothermia group. Delayed graft function developed in 
79 recipients of kidneys from donors in the hypothermia group 
(28%) and in 112 recipients of kidneys from donors in the nor-
mothermia group (39%). The primary efficacy analysis showed 
that hypothermia, as compared with normothermia, significantly 
reduced the odds of delayed graft function (odds ratio, 0.62; 95% 
confidence interval [CI], 0.43 to 0.92; P=0.02).
In an analysis involving donors who were expanded-criteria donors, 
hypothermia significantly reduced the odds of delayed graft func-
tion in this subgroup - 31.0% in the hypothermia group compared 
with 56.5% in the normothermia group with the adjusted odds ratio 
for the development of DGF being 0.31 (95% CI, 0.15 to 0.68; 
P=0.003).
Among standard-criteria donors, the rate of delayed graft func-
tion was lower in the hypothermia group than in the normothermia 
group (27.3% vs. 33.6%). The odds of delayed graft function were 
lower though not statistically significant (adjusted odds ratio, 0.71; 
95% CI, 0.45 to 1.13; P=0.15).
In terms of secondary outcomes, the overall number of organs 
transplanted from each donor and the rate of organs transplanted 
in each treatment group. There were four adverse events in organ 
donors: one episode of dysrhythmia and one episode of systemic 
hypertension in the hypothermia group and two episodes of cardiac 
arrest before organ recovery in the normothermia group.
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Conclusions
Targeted temperature control in donors had a statistically and 
clinically significant protective effect on renal-graft outcomes in 
recipients.
Abstract adapted from the original provided courtesy of PubMed: 
A service of the National Library of Medicine and the National 
Institutes of Health. 
Commentary
Renal transplantation accounts for the majority of organ trans-
planted in the United States each year. Delayed graft function 
(DGF) incurs a significant negative impact of organ recipients and 
the health care system1. The frequency of DGF varies from 4 to 10% 
in living donor transplants and 5 to 50% in deceased donor kidney 
transplants2. In 1995, Terasaki et al.3 showed that graft survival for 
living unrelated donation is superior compared to deceased dona-
tion. This thought to be due to numerous pathophysiologic changes 
that occur in brain death that potentially contribute to DGF in the 
transplanted kidney4.
In this randomized controlled trial, subjects were either warmed 
to 36.5–37.5 or cooled to 34–35°C with the goal of reaching the 
target temperature within 4 hours of enrollment. Temperature 
was maintained until transport to the operating room. The aver-
age time between declaration of death and organ recovery was 
approximately 30 hours. Based on cardiac arrest literature the goal 
duration of mild hypothermia (34°C) was at least 12 hours with 
median duration of hypothermia turning out to be 16.9 hours5.
Recipients were not randomly assigned but recipient characteris-
tics that were known to affect kidney-graft survival were balanced 
between the two treatment groups. The primary analysis adjusted 
for factors that were known to be associated with DGF such as 
the creatinine level at the time of consent, age, and cold-ischemia 
time were all significantly associated with delayed graft function. 
Hypothermia significantly decreased the rate of DGF (38% lower) 
when compared to the normothermia group). The trial demonstrated 
that noninvasive temperature-management aimed at hypothermia in 
donors decreased the rate of DGF in recipients.
This study is the first randomized controlled trial to employ 
hypothermia in potential renal donors. The data was collected in a 
prospective manner. The study investigators were not involved in 
the outcome assessment process. In the interim analysis the factors 
associated with DGF such as cold ischemia time, age and baseline 
creatinine were taken into account making this a well-designed ran-
domized controlled trial.
There are a number of limitations to this study. Health care pro-
viders who were caring for the donors were aware of the group 
assignments which could have introduced bias into care for the 
donors. Transplant surgeons had the opportunity to contact the PI 
or Co PI if there were questions concerning donor enrollment. No 
information on acute rejection or the potential long term effects on 
graft survival can be deduced currently. In addition, outcomes with 
respect to other organs were not stated. The investigators excluded 
hemodynamically unstable and coagulopathic donors which 
impacts the generalizability of the study. Recipients’ ethnicities 
are not stated in the analysis. It is known that African –American 
ethnicity is a risk factor for DGF6. No data is provided on adherence 
to intervention and how temperature variations were dealt with. The 
authors did not include details of the fluid management of donors or 
recipients, for example, chloride liberal versus restrictive7.
The study protocol mentions that subjects were warmed to 36.5–
37.5. The method and duration of warming was not included in 
the protocol. In hypothermia trials passive rewarming was utilized 
since active rewarming is associated with worse reperfusion injury.
This study was terminated prematurely. A systematic review of ran-
domized trials (RCT) stopped early for benefit by Montori et al. 
20058 showed that RCTs that stopped early show implausibly large 
treatment effects, particularly when the number of events is small. 
A Systematic Review and Meta-regression Analysis on stopping 
RCTs early for benefit and the estimation of treatment effects by 
Bassler et al.9 in 2010 showed that truncated RCTs were associated 
with greater effect sizes than RCTs not stopped early. This differ-
ence was independent of the presence of statistical stopping rules 
and was greatest in smaller studies. This renders the current results 
of this study preliminary. Further trials are therefore required prior 
to utilizing hypothermia as a standard of practice in this specific 
patient population.
Recommendation
This is the first RCT to investigate hypothermia in renal donors and 
measure recipient outcomes. The results of this study must be inter-
preted with caution based on the aforementioned reasons.
However, therapeutic hypothermia is both simple and incurred no 
adverse events. It may be applicable in donors who are relatively 
hemodynamically stable and not coagulopathic. From a practical 
view point, in the absence of another RCT addressing this issue, 
one may consider therapeutic hypothermia in potential renal 
transplant donors.
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